GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Tax Provision

AdAlta (ASX:1AD) Tax Provision : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is AdAlta Tax Provision?

AdAlta's tax provision for the six months ended in Dec. 2023 was A$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.


AdAlta Tax Provision Historical Data

The historical data trend for AdAlta's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AdAlta Tax Provision Chart

AdAlta Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Tax Provision
Get a 7-Day Free Trial - - - - -

AdAlta Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AdAlta Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AdAlta (ASX:1AD) Business Description

Traded in Other Exchanges
N/A
Address
2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083
AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.

AdAlta (ASX:1AD) Headlines

No Headlines